Odanacatib, a New Drug for the Treatment of Osteoporosis: Review of the Results in Postmenopausal Women

Table 1

Effect of 50 mg of odanacatib on formation markers and resorption at 12, 24, and 36 months.

	12 months	24 months	36 months
BSAP	−18%	−15%	+18%
NTx/Cr	−60.2%	−51.8%	−50%
CTx	−60%	−45%	−24%

NTx/Cr: N-terminal telopeptide of type I collagen normalized to creatinine.
BSAP: bone-specific alkaline phosphatase.
CTx: carboxyterminal telopeptide of type I collagen.